Prothrombin complex concentrates in cardiac surgery: where are we?

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Major bleeding is a common complication in cardiac surgery.
• Historically, fresh frozen plasma (FFP) was the primary treatment for bleeding.
• FFP use is linked to increased red blood cell (RBC) transfusions and costs.

Purpose of the Study:

• Compare and contrast FFP and prothrombin complex concentrates (PCCs) for managing major bleeding in cardiac surgery.
• Review PCC components, limitations, and risks.
• Discuss current evidence comparing PCC and FFP efficacy and safety.

Main Methods:

• Literature review and meta-analysis of studies comparing FFP and PCC in cardiac surgery.
• Analysis of coagulation factor content, administration times, and safety profiles.
• Evaluation of impact on RBC transfusion rates and healthcare costs.

Main Results:

• Prothrombin complex concentrates (PCCs) are more effective than FFP in reducing RBC transfusions and associated costs.
• Four-factor PCC (4F-PCC) demonstrates a favorable safety profile.
• PCCs offer advantages in volume, factor concentration, and administration speed.

Conclusions:

• Current evidence supports using 4F-PCC over FFP as the primary hemostatic agent for major bleeding in cardiac surgery.
• 4F-PCC use is associated with decreased RBC transfusion rates and maintains safety.
• PCCs provide significant benefits including smaller volume, higher factor concentration, and faster administration.